We just covered the 14 Best Low Risk High Growth Stocks to Buy Right Now and AstraZeneca PLC (NYSE:AZN) ranks 5th on this list.
The growth story for AstraZeneca PLC (NYSE:AZN) is built on a massive, contractually visible expansion plan. Earlier this year, CEO Pascal Soriot reaffirmed the company’s goal to reach $80 billion in annual revenue by 2030. For a company currently reporting roughly $59 billion, this represents an industry-leading growth trajectory. In Q1 2026, cancer drug sales jumped 20%, fueled by blockbuster performance from Tagrisso, Imfinzi, and the accelerating Enhertu portfolio. These high-margin antibody-drug conjugates are viewed by hedge funds as the primary growth engine for the next decade. Safety in pharma comes from having so many products that a single failure cannot sink the stock. AstraZeneca owns 16 different blockbuster medicines, drugs generating over $1 billion annually.
In 2026 alone, AstraZeneca PLC (NYSE:AZN) is expecting results from more than 20 Phase III clinical trials. This strategy significantly de-risks the portfolio, as consistent positive readouts, like the recent Tozorakimab and Imfinzi successes in early April, provide a steady stream of new revenue. The firm is also uniquely positioned to handle geopolitical shifts better than many US-centric peers. Despite broader trade tensions, AstraZeneca is the largest multinational pharmaceutical company in China. In early 2026, it pledged an additional $15 billion in investments there, capturing high-volume demand in the world’s second-largest market.
While we acknowledge the potential of AZN as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
READ NEXT: Israel Englander Stock Portfolio: Top 10 Stock Picks and Billionaire Stan Druckenmiller’s 10 Small and Mid-Cap Stock Picks with Huge Upside Potential.
Disclosure: None. Follow Insider Monkey on Google News.
